SG11202104441QA - Humanized antibodies against c-kit - Google Patents
Humanized antibodies against c-kitInfo
- Publication number
- SG11202104441QA SG11202104441QA SG11202104441QA SG11202104441QA SG11202104441QA SG 11202104441Q A SG11202104441Q A SG 11202104441QA SG 11202104441Q A SG11202104441Q A SG 11202104441QA SG 11202104441Q A SG11202104441Q A SG 11202104441QA SG 11202104441Q A SG11202104441Q A SG 11202104441QA
- Authority
- SG
- Singapore
- Prior art keywords
- kit
- antibodies against
- humanized antibodies
- humanized
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862771526P | 2018-11-26 | 2018-11-26 | |
| PCT/US2019/063091 WO2020112687A2 (en) | 2018-11-26 | 2019-11-25 | Humanized antibodies against c-kit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202104441QA true SG11202104441QA (en) | 2021-06-29 |
Family
ID=70769872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202104441QA SG11202104441QA (en) | 2018-11-26 | 2019-11-25 | Humanized antibodies against c-kit |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11208482B2 (en) |
| EP (1) | EP3817773A4 (en) |
| JP (2) | JP7166457B2 (en) |
| KR (1) | KR20210094610A (en) |
| CN (1) | CN113194991A (en) |
| AU (1) | AU2019386976B2 (en) |
| BR (1) | BR112021008454A2 (en) |
| CA (1) | CA3117816A1 (en) |
| CL (1) | CL2021001366A1 (en) |
| CO (1) | CO2021006869A2 (en) |
| CR (1) | CR20210272A (en) |
| DO (1) | DOP2021000101A (en) |
| EA (1) | EA202190986A1 (en) |
| IL (1) | IL282668A (en) |
| MX (1) | MX2021006134A (en) |
| PE (1) | PE20211786A1 (en) |
| PH (1) | PH12021551126A1 (en) |
| SG (1) | SG11202104441QA (en) |
| WO (1) | WO2020112687A2 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210094610A (en) | 2018-11-26 | 2021-07-29 | 포티 세븐, 인코포레이티드 | Humanized Antibodies to c-Kit |
| AU2019390394B2 (en) | 2018-11-28 | 2023-11-30 | Forty Seven, Inc. | Genetically modified HSPCs resistant to ablation regime |
| JP2022533253A (en) * | 2019-05-24 | 2022-07-21 | フォーティ セブン， インコーポレイテッド | Simultaneous administration regimen of immunotherapeutic agents for c-kit and CD47 |
| US11692038B2 (en) | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
| KR20230145381A (en) * | 2021-02-09 | 2023-10-17 | 재스퍼 테라퓨틱스 인코포레이티드 | Modified Stem Cell Compositions and Methods of Use |
| WO2023069961A1 (en) * | 2021-10-18 | 2023-04-27 | Jasper Therapeutics, Inc. | Modified stem cell compositions and methods for use |
| WO2023111311A1 (en) | 2021-12-16 | 2023-06-22 | Universität Basel | Discernible cell surface protein variants of cd117 for use in cell therapy |
| WO2023204547A1 (en) * | 2022-04-18 | 2023-10-26 | 주식회사 노벨티노빌리티 | C-kit targeting immunoconjugate comprising pseudomonas exotoxin a |
| WO2024008910A1 (en) | 2022-07-07 | 2024-01-11 | Cimeio Therapeutics Ag | Antibodies targeting cd117 |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| US5821108A (en) | 1995-04-07 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Enrichment for a thymocyte subset having progenitor cell activity using c-kit as a selection marker |
| DE19539493A1 (en) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Strong homologous promoter from hamster |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| DE60045319D1 (en) | 1999-02-05 | 2011-01-13 | Samsung Electronics Co Ltd | Method and apparatus for retrieving texture images |
| EP1539233B1 (en) | 2001-07-12 | 2011-04-27 | FOOTE, Jefferson | Super humanized antibodies |
| DE50308030D1 (en) | 2002-11-29 | 2007-10-04 | Boehringer Ingelheim Pharma | NEW NEOMYCIN PHOSPHOTRANSFERASE GENES AND METHOD FOR SELECTION OF HIGHLY PRODUCTIVE RECOMBINANT CELLS |
| DE10338531A1 (en) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for recloning production cells |
| JP4620739B2 (en) | 2004-11-10 | 2011-01-26 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | Use of flow cytometry analysis to optimize cell preservation strategies for CHO cells |
| TWI395754B (en) | 2006-04-24 | 2013-05-11 | Amgen Inc | Humanized c-kit antibody |
| US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| EP2088864B1 (en) | 2006-11-03 | 2017-08-16 | The Board of Trustees of the Leland Stanford Junior University | Selective immunodepletion of endogenous stem cell niche for engraftment |
| EP2522730A1 (en) | 2007-03-02 | 2012-11-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Improvement of protein production |
| EP2031064A1 (en) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Method for increasing protein titres |
| PT3056515T (en) | 2008-01-15 | 2019-07-19 | Univ Leland Stanford Junior | Methods for manipulating phagocytosis mediated by cd47 |
| DK3043181T3 (en) | 2008-01-15 | 2020-05-04 | Univ Leland Stanford Junior | MARKERS OF ACUTE MYELOID LEUKEMY STEM CELLS |
| US20120253017A1 (en) * | 2009-05-28 | 2012-10-04 | Victoria Ballard | Stem cell targeting |
| EP4134095A1 (en) | 2009-09-15 | 2023-02-15 | The Board of Trustees of the Leland Stanford Junior University | Synergistic anti-cd47 therapy for hematologic cancers |
| US20120283124A1 (en) | 2009-11-10 | 2012-11-08 | Park Christopher Y | Cell Surface Marker Expression in Hematopoietic Stem Cells and Progenitors for the Diagnosis, Prognosis, and Treatment of Myelodysplastic Syndromes |
| DK3789038T3 (en) | 2010-05-14 | 2022-10-17 | Univ Leland Stanford Junior | HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODIES AGAINST CD47 |
| AR086044A1 (en) | 2011-05-12 | 2013-11-13 | Imclone Llc | ANTIBODIES THAT SPECIFICALLY JOIN A C-KIT EXTRACELLULAR DOMAIN AND USES OF THE SAME |
| NZ628433A (en) | 2012-01-20 | 2017-02-24 | Immunophotonics Inc | Chitosan-derived compositions |
| AU2013295848B2 (en) * | 2012-07-25 | 2018-05-24 | Celldex Therapeutics, Inc. | Anti-KIT antibodies and uses thereof |
| JP6255408B2 (en) | 2012-09-25 | 2017-12-27 | コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． | Treatment system |
| KR20150143458A (en) * | 2013-03-06 | 2015-12-23 | 메리맥 파마슈티컬즈, 인크. | ANTI-C-MET Tandem Fc Bispecific Antibodies |
| EP2968590B1 (en) * | 2013-03-15 | 2018-09-05 | Novartis AG | Antibody drug conjugates |
| AR100280A1 (en) * | 2014-05-22 | 2016-09-21 | Rohm & Haas | POLYMER BINDERS FOR INK JET PRINTERS |
| US10786578B2 (en) * | 2014-08-05 | 2020-09-29 | Novartis Ag | CKIT antibody drug conjugates |
| CA3229961A1 (en) | 2014-08-26 | 2016-03-03 | The Board Of Trustees Of The Leland Stanford Junior University | Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling |
| BR112017021536A2 (en) | 2015-04-06 | 2018-07-03 | Harvard College | compositions and methods for nonmyeloablative conditioning |
| US10358472B2 (en) | 2015-05-06 | 2019-07-23 | The Board Of Trustees Of The Leland Stanford Junior University | High affinity CD47 analogs |
| DK3298043T3 (en) | 2015-05-18 | 2021-02-15 | Ab Initio Biotherapeutics Inc | SIRP polypeptide compositions and methods of use |
| CN117695387A (en) | 2016-04-15 | 2024-03-15 | 小利兰·斯坦福大学托管委员会 | Methods for determining and achieving a therapeutically effective dose of an anti-CD 47 agent for treating cancer |
| SG11201811290VA (en) | 2016-06-17 | 2019-01-30 | Magenta Therapeutics Inc | Compositions and methods for the depletion of cd117+cells |
| JOP20190155A1 (en) | 2016-12-21 | 2019-06-23 | Novartis Ag | Antibody drug conjugates for ablating hematopoietic stem cells |
| US20180214524A1 (en) | 2017-01-30 | 2018-08-02 | The Board Of Trustees Of The Leland Stanford Junior University | Non-genotoxic conditioning regimen for stem cell transplantation |
| PT3642242T (en) | 2017-06-21 | 2024-04-16 | Univ Leland Stanford Junior | Dosing parameters for cd47 targeting therapies to hematologic malignancies |
| PL3658589T3 (en) | 2017-07-26 | 2024-03-18 | Forty Seven, Inc. | Anti-sirp-alpha antibodies and related methods |
| KR20210094610A (en) | 2018-11-26 | 2021-07-29 | 포티 세븐, 인코포레이티드 | Humanized Antibodies to c-Kit |
| AU2019390394B2 (en) | 2018-11-28 | 2023-11-30 | Forty Seven, Inc. | Genetically modified HSPCs resistant to ablation regime |
| JP2022533253A (en) | 2019-05-24 | 2022-07-21 | フォーティ セブン， インコーポレイテッド | Simultaneous administration regimen of immunotherapeutic agents for c-kit and CD47 |
-
2019
- 2019-11-25 KR KR1020217019482A patent/KR20210094610A/en not_active Application Discontinuation
- 2019-11-25 EP EP19890096.1A patent/EP3817773A4/en active Pending
- 2019-11-25 SG SG11202104441QA patent/SG11202104441QA/en unknown
- 2019-11-25 BR BR112021008454-1A patent/BR112021008454A2/en active Search and Examination
- 2019-11-25 MX MX2021006134A patent/MX2021006134A/en unknown
- 2019-11-25 CR CR20210272A patent/CR20210272A/en unknown
- 2019-11-25 WO PCT/US2019/063091 patent/WO2020112687A2/en unknown
- 2019-11-25 CN CN201980077493.XA patent/CN113194991A/en active Pending
- 2019-11-25 AU AU2019386976A patent/AU2019386976B2/en active Active
- 2019-11-25 PE PE2021000758A patent/PE20211786A1/en unknown
- 2019-11-25 US US16/694,975 patent/US11208482B2/en active Active
- 2019-11-25 JP JP2021529294A patent/JP7166457B2/en active Active
- 2019-11-25 CA CA3117816A patent/CA3117816A1/en active Pending
- 2019-11-25 EA EA202190986A patent/EA202190986A1/en unknown
-
2020
- 2020-12-29 US US17/137,228 patent/US11041022B2/en active Active
-
2021
- 2021-04-26 IL IL282668A patent/IL282668A/en unknown
- 2021-05-17 PH PH12021551126A patent/PH12021551126A1/en unknown
- 2021-05-25 CL CL2021001366A patent/CL2021001366A1/en unknown
- 2021-05-25 CO CONC2021/0006869A patent/CO2021006869A2/en unknown
- 2021-05-25 DO DO2021000101A patent/DOP2021000101A/en unknown
- 2021-11-17 US US17/528,976 patent/US20220127358A1/en active Pending
-
2022
- 2022-07-13 JP JP2022112548A patent/JP2022137208A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP3817773A2 (en) | 2021-05-12 |
| CO2021006869A2 (en) | 2021-06-10 |
| PE20211786A1 (en) | 2021-09-09 |
| EP3817773A4 (en) | 2021-09-15 |
| WO2020112687A2 (en) | 2020-06-04 |
| US20210122822A1 (en) | 2021-04-29 |
| CA3117816A1 (en) | 2020-06-04 |
| AU2019386976A1 (en) | 2021-06-03 |
| WO2020112687A3 (en) | 2020-08-20 |
| EA202190986A1 (en) | 2021-12-14 |
| BR112021008454A2 (en) | 2021-10-05 |
| CL2021001366A1 (en) | 2021-11-19 |
| JP2022507962A (en) | 2022-01-18 |
| JP2022137208A (en) | 2022-09-21 |
| KR20210094610A (en) | 2021-07-29 |
| JP7166457B2 (en) | 2022-11-07 |
| US11041022B2 (en) | 2021-06-22 |
| PH12021551126A1 (en) | 2022-02-21 |
| IL282668A (en) | 2021-06-30 |
| AU2019386976B2 (en) | 2024-05-30 |
| MX2021006134A (en) | 2021-06-23 |
| US20200165337A1 (en) | 2020-05-28 |
| US20220127358A1 (en) | 2022-04-28 |
| US11208482B2 (en) | 2021-12-28 |
| DOP2021000101A (en) | 2021-09-30 |
| CN113194991A (en) | 2021-07-30 |
| CR20210272A (en) | 2021-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275657A (en) | C-kit antibodies | |
| IL280780A (en) | Anti-tigit antibodies | |
| IL282668A (en) | Humanized antibodies against c-kit | |
| IL279352A (en) | Il-11ra antibodies | |
| IL280013A (en) | Anti-il36r antibodies | |
| IL283812A (en) | Humanized anti-human-pd-1 antibody | |
| IL278010A (en) | Galectin-10 antibodies | |
| IL282756A (en) | Humanized anti-sirpα antibodies | |
| IL277030A (en) | Antibodies | |
| IL262776A (en) | Humanized anti-il-1r3 antibodies | |
| GB202110263D0 (en) | Anti-btla antibodies | |
| SG11202007735TA (en) | Anti-her2 antibodies | |
| IL281594A (en) | Anti-klrg1 antibodies | |
| GB2581174B (en) | Antibodies against hEPCR | |
| IL279823A (en) | Humanized antibodies against psma | |
| GB201806084D0 (en) | Antibodies | |
| GB201911211D0 (en) | Monoclonal antibodies against ambra-1 | |
| GB201819952D0 (en) | Antibodies | |
| GB201817309D0 (en) | Antibodies | |
| GB201817311D0 (en) | Antibodies | |
| GB201817313D0 (en) | Antibodies | |
| GB201817312D0 (en) | Antibodies | |
| SG11202105718TA (en) | Modified antibodies | |
| GB201806099D0 (en) | Galectin-10 Antibodies | |
| GB201804269D0 (en) | Murine antibodies |